Advertisement
The line-up of sessions that feature the first pro-healing stent, which isan alternative to drug-eluting stents, includes:
In addition, the latest results from clinical trials of the Genous stentwill be discussed by Robbert de Winter, M.D., Ph.D., principal investigatorand director of the catheterization laboratory at the Academic Medical Centerin Amsterdam. Specifically, de Winter will present:
Advertisement
Unlike drug-eluting stents, Genous, which is coated with an antibody,captures a patient's endothelial progenitor cells (EPCs) to accelerate thenatural healing process. EPCs circulate in the bloodstream and are involvedin the repair of blood vessels. When attracted to the surface of Genous, EPCsrapidly form an endothelial layer over the stent that provides protectionagainst thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative medicaldevices for the treatment of vascular diseases. The company's productportfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelialprogenitor cells (EPCs) to accelerate the natural healing process followingplacement. Other products are stents, balloons and guiding catheters marketedunder the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), AvitaHP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and hasoperations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen,China. OrbusNeich, which has provided cardiology devices to physiciansthrough its predecessor companies since 1979, today supplies products in morethan 60 countries. For more information, visit www.OrbusNeich.com.- Interventional Strategies and Adjunct Pharmacology in ACS and AMI; Should Specialized DES for AMI be Developed? Early Experience with EPC Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of Cardiology, ISALA Klinieken, Hospital De Weezenlanden, Zwolle, The Netherlands; 2:10 p.m. EDT on Oct. 21; Room 151B - Innovative Devices and Futuristic Concepts: Novel Bare Metal and Drug- Eluting Stents; The Genous Stent Coating with CD34 Antibodies to Actively Capture Circulating EPCs: Design Parameters and Effects on Healing and Thrombogenicity; Michael Kutryk, M.D., clinician scientist and interventional cardiologist at St. Michael's Hospital, assistant professor at the University of Toronto; Canada; 3:08 p.m. EDT on Oct. 21; Room 152A
SOURCE OrbusNeich
